Vanda Pharmaceuticals Initiates Thetis Study of Nereus for GLP-1–Induced Vomiting Prevention

Why It Matters

If successful, Nereus could become the first approved therapy to mitigate a common side effect of popular weight‑loss drugs, unlocking broader market adoption. This would give Vanda a differentiated asset in the rapidly expanding GLP‑1 therapeutic space.

Key Takeaways

• Thetis study evaluates Nereus vs placebo for GLP‑1‑induced vomiting
• Primary endpoint: proportion of patients free from any vomiting episode
• Phase‑II data showed 29.3% vomiting vs 58.6% with placebo
• Topline results expected Q4 2026; NDA may need extra data

Pulse Analysis

GLP‑1 receptor agonists such as semaglutide and tirzepatide have reshaped obesity and diabetes treatment, but gastrointestinal side effects—particularly nausea and vomiting—remain a barrier to patient adherence. Clinicians often resort to dose titration or adjunct anti‑emetics, which can blunt the drugs’ efficacy and increase healthcare costs. A dedicated therapy that prevents vomiting could therefore expand the addressable market, allowing physicians to prescribe optimal doses from the outset.

Vanda Pharmaceuticals’ candidate tradipitant, branded Nereus, targets the neurokinin‑1 receptor, a pathway implicated in the emetic response. In a Phase‑II trial, a single 1 mg dose of tradipitant reduced vomiting after a Wegovy injection from 58.6% to 29.3% and lowered nausea‑related vomiting from 48.3% to 22.4%. These results suggest a robust pharmacologic effect that justifies the larger, double‑blind Thetis study. By focusing on the proportion of patients who remain completely vomiting‑free, Vanda aims to demonstrate a clinically meaningful benefit that regulators can readily quantify.

Should the Thetis trial meet its primary endpoint, Vanda could position Nereus as the first FDA‑approved anti‑vomiting agent for GLP‑1 therapies, a niche with limited competition. The timing aligns with the projected $30 billion GLP‑1 market by 2030, offering a potential revenue stream that complements Vanda’s existing psychiatric portfolio. However, the company’s note that additional data may be needed before filing an NDA underscores the regulatory uncertainty typical of novel indication extensions. Investors will watch the Q4 2026 readout closely, as it could reshape the therapeutic landscape for obesity and diabetes management.